Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction.

Area of Science:

• Cardiovascular Biology
• Metabolic Regulation
• Vascular Physiology

Background:

• Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge, particularly in elderly, diabetic, and hypertensive populations.
• The pathophysiology of HFpEF, especially diastolic dysfunction, remains poorly understood, and effective treatments are lacking.
• Coronary microvascular rarefaction and reduced coronary flow reserve (CFR) are increasingly recognized as key contributors to HFpEF.

Purpose of the Study:

• To review the role of Sirtuin 3 (SIRT3) in endothelial cell (EC) metabolism.
• To explore the link between SIRT3-mediated EC metabolism, coronary microvascular rarefaction, and the development of HFpEF.
• To summarize current knowledge on SIRT3's impact on angiogenesis and vascular homeostasis in the context of HFpEF.

Main Methods:

• Literature review of current research on SIRT3, EC metabolism, and HFpEF.
• Analysis of molecular mechanisms linking SIRT3 to endothelial function and angiogenesis.
• Synthesis of findings from clinical and preclinical studies on coronary microvascular rarefaction and diastolic dysfunction.

Main Results:

• Endothelial cells rely on glycolysis for function; SIRT3 regulates this metabolic pathway.
• Disruption of SIRT3 in ECs impairs glycolytic metabolism and angiogenesis.
• Impaired angiogenesis and altered EC metabolism contribute to cardiomyocyte hypoxia, fibrosis, and diastolic dysfunction in HFpEF.

Conclusions:

• SIRT3 plays a critical role in maintaining endothelial cell metabolism and vascular health.
• Dysfunctional SIRT3-mediated EC metabolism contributes to coronary microvascular rarefaction and diastolic dysfunction in HFpEF.
• Targeting SIRT3 in endothelial cells may represent a novel therapeutic strategy for HFpEF.